BioCentury
ARTICLE | Finance

Tuned up for cash flow

Exosome raises $27M to begin selling its biofluid-based cancer tests

March 17, 2014 7:00 AM UTC

Exosome Diagnostics Inc. will use its $27 million series B round to begin a commercial push of tests created with its minimally invasive, fluid-based molecular diagnostic platform.

Partner Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) co-led the round along with another new investor, Arcus Ventures. Also new to the syndicate were Tiger Partners; CD Ventures; and Monashee Capital. Existing investors NGN Capital and Forbion Capital participated as well...